Cargando…

Anti–Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis()

This systematic review and meta-analysis evaluated anti–programmed cell death (PD)-1 immunotherapy (nivolumab or pembrolizumab) for overall efficacy, safety, and effective dose relative to standard chemotherapy or other conventional drugs in the treatment of malignant tumors. We searched the followi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ran, Peng, Pei-Chun, Wen, Bin, Li, Fu-Ying, Xie, Sheng, Chen, Guozhong, Lu, Jiefu, Peng, Zhuoyu, Tang, Shao-Bo, Liang, Yu-Mei, Deng, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2016
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800062/ https://www.ncbi.nlm.nih.gov/pubmed/26947879 http://dx.doi.org/10.1016/j.tranon.2015.11.010

Ejemplares similares

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
por: Guo, Liting, et al.
Publicado: (2017)

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management
por: Shen, John, et al.
Publicado: (2018)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
por: Lattanzi, Michael, et al.
Publicado: (2018)

Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
por: Zhang, Shushan, et al.
Publicado: (2023)

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
por: Huang, Jumin, et al.
Publicado: (2022)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
por: Lu, Jia, et al.
Publicado: (2022)

Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
por: Al Jarroudi, Ouissam, et al.
Publicado: (2020)

Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report
por: Feng, Yu, et al.
Publicado: (2019)

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
por: Liu, Nian, et al.
Publicado: (2023)

DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Zhu, Zhongling, et al.
Publicado: (2018)

Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
por: Peng, Xiaopeng, et al.
Publicado: (2023)

Programmed Cell Death Protein‐1 (PD‐1)‐Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World
por: Cui, Hanzhi, et al.
Publicado: (2020)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

Therapeutic Effect of an Anti-Human Programmed Death-Ligand 1 (PD-L1) Nanobody on Polymicrobial Sepsis in Humanized Mice
por: Zhao, Zhen-zhen, et al.
Publicado: (2021)

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
por: Li, Bin, et al.
Publicado: (2020)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
por: Pei, Liping, et al.
Publicado: (2023)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature
por: Gunjur, Ashray, et al.
Publicado: (2019)

T Cell Invigoration is Associated with the Clinical Response to Anti-PD-1-Based Immunotherapy in Non-Small Cell Lung Cancer
por: Wu, Hui, et al.
Publicado: (2023)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention
por: Chen, Jie, et al.
Publicado: (2019)

Regulated Cell Death in Urinary Malignancies
por: Nie, Zhenyu, et al.
Publicado: (2021)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
por: Moon, Yujeong, et al.
Publicado: (2022)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
por: Zheng, Yi, et al.
Publicado: (2019)

Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy
por: Chen, Jierong, et al.
Publicado: (2022)

Eubacterium rectale Improves the Efficacy of Anti-PD1 Immunotherapy in Melanoma via l-Serine-Mediated NK Cell Activation
por: Liu, Nian, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
por: Xu, Liqin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_krteoeu8verq9gdiuo7n09j6b3